Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Mirati Therapeutics, Inc. (NASDAQ:MRTX – Get Rating) Director Julie M. Cherrington sold 2,546 shares of the stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $44.66, for a total transaction of $113,704.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Mirati Therapeutics Stock Performance
Shares of MRTX traded up $2.16 during midday trading on Friday, hitting $45.14. 17,010 shares of the stock traded hands, compared to its average volume of 1,458,775. Mirati Therapeutics, Inc. has a 1-year low of $32.96 and a 1-year high of $124.82. The firm has a market capitalization of $2.60 billion, a PE ratio of -3.21 and a beta of 1.07. The business’s 50 day moving average price is $58.13 and its two-hundred day moving average price is $66.98.
Mirati Therapeutics (NASDAQ:MRTX – Get Rating) last issued its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($3.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.46) by $0.37. Mirati Therapeutics had a negative return on equity of 60.40% and a negative net margin of 6,253.81%. The firm had revenue of $5.43 million during the quarter, compared to analyst estimates of $4.72 million. As a group, equities research analysts forecast that Mirati Therapeutics, Inc. will post -13.5 EPS for the current fiscal year.
Institutional Trading of Mirati Therapeutics
A number of hedge funds have recently modified their holdings of MRTX. Bank Julius Baer & Co. Ltd Zurich raised its holdings in Mirati Therapeutics by 41.7% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,481 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 730 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Mirati Therapeutics by 77.3% during the second quarter. Virtus ETF Advisers LLC now owns 1,975 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 861 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of Mirati Therapeutics during the third quarter worth $42,000. Credit Suisse AG raised its stake in shares of Mirati Therapeutics by 0.3% during the second quarter. Credit Suisse AG now owns 442,710 shares of the biotechnology company’s stock worth $29,719,000 after buying an additional 1,123 shares during the last quarter. Finally, US Bancorp DE lifted its stake in shares of Mirati Therapeutics by 77.5% in the 2nd quarter. US Bancorp DE now owns 3,369 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 1,471 shares during the period.
Analysts Set New Price Targets
MRTX has been the topic of several research reports. StockNews.com raised shares of Mirati Therapeutics to a “sell” rating in a report on Friday, January 13th. Stifel Nicolaus cut their price objective on Mirati Therapeutics to $73.00 in a report on Friday, December 9th. B. Riley began coverage on Mirati Therapeutics in a research note on Friday, October 28th. They set a “neutral” rating and a $72.00 price objective for the company. Needham & Company LLC assumed coverage on shares of Mirati Therapeutics in a report on Wednesday, December 14th. They issued a “hold” rating for the company. Finally, Citigroup lowered shares of Mirati Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $121.00 to $53.00 in a research note on Friday, December 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $83.20.
Mirati Therapeutics Company Profile
(Get Rating)
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.
See Also
- Get a free copy of the StockNews.com research report on Mirati Therapeutics (MRTX)
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mirati Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Mirati Therapeutics wasn’t on the list.
While Mirati Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
